U.S. Markets close in 3 hrs 29 mins

FDA approves Jazz Pharmaceuticals sleep disorder drug

John George
FDA approves Jazz Pharmaceuticals sleep disorder drug

The Food and Drug Administration approved Jazz Pharmaceuticals' new drug application for Sunosi, a once-daily medicine designed to improve wakefulness in adult patients suffering from narcolepsy and obstructive sleep apnea. Sunosi is expected to be commercially available in the United States following the final scheduling decision by the U.S. Drug Enforcement Administration, which is typically rendered within 90 days of FDA approval. Jazz Pharmaceuticals, which is based in Dublin, Ireland, has major operations in Philadelphia where the company has about 160 employees.